About this Journal Submit a Manuscript Table of Contents
Advances in Preventive Medicine
Volume 2013 (2013), Article ID 346372, 10 pages
http://dx.doi.org/10.1155/2013/346372
Review Article

30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs

1The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, 160 Water Street, FL 24, New York, NY 10038, USA
2Department of Psychiatry and Behavioral Medicine, Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, WI 53226, USA
3NYU College of Nursing, New York, NY 10003, USA
4Rollins School of Public Health, Emory University, Atlanta, GA 30329, USA
5Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, 11527 Athens, Greece
6Department of Public Health, University of Tartu, 50411 Tartu, Estonia

Received 16 October 2012; Revised 11 March 2013; Accepted 18 May 2013

Academic Editor: Catherine Hankins

Copyright © 2013 D. C. Des Jarlais et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. M. Mathers, L. Degenhardt, B. Phillips et al., “Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review,” The Lancet, vol. 372, no. 9651, pp. 1733–1745, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. UNAIDS, UNAIDS Report on the Global AIDS Epidemic, edited by HIV/AIDS JUNPo, UNAIDS, 2012.
  3. B. Conway, J. Prasad, R. Reynolds et al., “Directly observed therapy for the management of HIV-infected patients in a methadone program,” Clinical Infectious Diseases, vol. 38, supplement 5, pp. S402–S408, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. McNeil, “Global fund sees changes, not all of them welcomed,” in New York Times, New York Times, New York, NY, USA, 2012.
  5. CDC CfDC, “First report of AIDS,” in MMWR Weekly Report, vol. 50, Centers for Disease Control, Atlanta, GA, USA, 1981.
  6. S. D. Holmberg, “The estimated prevalence and incidence of HIV in 96 large US metropolitan areas,” American Journal of Public Health, vol. 86, no. 5, pp. 642–654, 1996. View at Scopus
  7. R. Robertson and A. Richardson, “Heroin injecting and the introduction of HIV/AIDS into a Scottish city,” Journal of the Royal Society of Medicine, vol. 100, no. 11, pp. 491–494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. H. J. A. van Haastrecht, J. A. R. van den Hoek, C. Bardoux, A. Leentvaar-Kuypers, and R. A. Coutinho, “The course of the HIV epidemic among intravenous drug users in Amsterdam, The Netherlands,” American Journal of Public Health, vol. 81, no. 1, pp. 59–62, 1991. View at Scopus
  9. C. van den Berg, C. Smit, G. van Brussel, R. Coutinho, and M. Prins, “Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users,” Addiction, vol. 102, no. 9, pp. 1454–1462, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. V. Stimson, “AIDS and injecting drug use in the United Kingdom, 1987–1993: the policy response and the prevention of the epidemic,” Social Science and Medicine, vol. 41, no. 5, pp. 699–716, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Wodak and L. Maher, “The effectiveness of harm reduction in preventing HIV among injecting drug users,” New South Wales public health bulletin, vol. 21, no. 3-4, pp. 69–73, 2010. View at Scopus
  12. D. F. Musto, “America's first cocaine epidemic,” The Wilson Quarterly, vol. 13, no. 3, 1989. View at Scopus
  13. W. Anderson, “The New York needle trial: the politics of public health in the age of AIDS,” American Journal of Public Health, vol. 81, no. 11, pp. 1506–1517, 1991. View at Scopus
  14. WHO UNODC and UNAIDS, WHO, UNODC, UNAIDS Technical Guide For Countries to Set Targets For Universal Access To HIV Prevention, Treamtent, and Care of Injection Drug Users, WHO, Geneva, Switzerland, 2009.
  15. C. Aceijas, G. V. Stimson, M. Hickman, and T. Rhodes, “Global overview of injecting drug use and HIV infection among injecting drug users,” AIDS, vol. 18, no. 17, pp. 2295–2303, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. D. C. Des Jarlais, J. P. Feelemyer, S. N. Modi et al., “Transitions from injection-drug-use-concentrated to self-sustaining heterosexual HIV epidemics: patterns in the international data,” Plos One, vol. 7, no. 3, article e31227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. C. Des Jarlais, H. Hagan, S. R. Friedman et al., “Maintaining low HIV seroprevalence in populations of injecting drug users,” Journal of the American Medical Association, vol. 274, no. 15, pp. 1226–1231, 1995. View at Scopus
  18. J. T. L. Iverson, H. Wand, J. Kaldor, and L. Maher, “Low Incidence of HIV among people who inject drugs over two decades in Australia,” in Proceedings of the International AIDS Conference, AIDS, Washington, DC, USA, July 2012.
  19. S. A. Strathdee, D. M. Patrick, S. L. Currie et al., “Needle exchange is not enough: lessons from the Vancouver injecting drug use study,” AIDS, vol. 11, no. 8, pp. F59–F65, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Paraskevis, G. Nikolopoulos, C. Tsiara et al., “HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report,” Eurosurveillance, vol. 16, no. 36, article 1, 2011. View at Scopus
  21. EMCDDA/ECDC, HIV in Injecting Drug Users in the EU/EEA, Following a Reported increase in Cases in Greece and Romania, Joint Publications, EMCDDA, Lisbon, Portugal, 2012.
  22. A. . Fotiou, K. Micha, D. Paraskevis, M. Terzidou, M. Malliori, and A. Hatzakis, HIV Outbreak Among Injecting Drug Users in Greece, EMCDDA, Athens, Greece, 2012.
  23. A. S. de Vos, J. J. van der Helm, M. Prins, and M. E. E. Kretzschmar, “Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam: evidence for harm reduction?” in Proceedings of the International AIDS Conference, Washington DC, USA, July 2012.
  24. EMCDDA, Health and Social Responses (HSR) 2009 Statistical Bulletin, Statistical Bulletins, EMCDDA, Lisbon, Portugal, 2009.
  25. D. C. Des Jarlais, K. Arasteh, C. McKnight et al., “HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors,” Drug and Alcohol Dependence, vol. 109, no. 1–3, pp. 154–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Rodes, M. Suarez, C. Menoyo, L. de la Fuente, A. Bolea, and F. Parras, “Implementation of comprehensive harm reduction interventions in Spain. 1993–2000,” in Proceedings of the XIV International AIDS Conference (IAC '12), pp. 22–27, Barcelona, Spain, July 2012.
  27. J. Montaner, V. D. Lim, B. Yip et al., “Expanded HAART coverage is associated with decreased HIV/AIDS morbidity and HIV new diagnoses: an update on the 'treatment as prevention' experience in British Columbia, Canada,” in Proceedings of the International AIDS Conference, Washington, DC, USA, 2012.
  28. B. M. Mathers, L. Degenhardt, H. Ali et al., “HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage,” The Lancet, vol. 375, no. 9719, pp. 1014–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Cohen, “No opiate substitutes for the masses of IDUs,” Science, vol. 329, no. 5988, pp. 165–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Rhodes, L. Mikhailova, A. Sarang et al., “Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment,” Social Science and Medicine, vol. 57, no. 1, pp. 39–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. R. E. Booth, J. Kennedy, T. Brewster, and O. Semerik, “Drug injectors and dealers in Odessa, Ukraine,” Journal of Psychoactive Drugs, vol. 35, no. 4, pp. 419–426, 2003. View at Scopus
  32. D. Wolfe, M. P. Carrieri, and D. Shepard, “Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward,” The Lancet, vol. 376, no. 9738, pp. 355–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Burki, “Russia's drug policy fuels infectious disease epidemics,” The Lancet Infectious Diseases, vol. 12, no. 4, pp. 275–276, 2012.
  34. D. Wolfe, “Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union,” International Journal of Drug Policy, vol. 18, no. 4, pp. 246–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Uusküla, M. Kals, K. Denks et al., “The prevalence of chlamydial infection in Estonia: a population-based survey,” International Journal of STD and AIDS, vol. 19, no. 7, pp. 455–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Uusküla, L. A. McNutt, J. Dehovitz, K. Fischer, and R. Heimer, “High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia,” International Journal of STD and AIDS, vol. 18, no. 1, pp. 41–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. D. Pinkerton, “How many HIV infections are prevented by Vancouver Canada's supervised injection facility?” International Journal of Drug Policy, vol. 22, no. 3, pp. 179–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. E. H. Kaplan, “Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries,” Reviews of Infectious Diseases, vol. 11, no. 2, pp. 289–298, 1989. View at Scopus
  39. S. A. Strathdee, T. B. Hallett, N. Bobrova et al., “HIV and risk environment for injecting drug users: the past, present, and future,” The Lancet, vol. 376, no. 9737, pp. 268–284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Raymond, HIV Prevention Funding: Transmission Problems, 2012.
  41. J. Blanchard, Summary of Interim Results From the Winnipeg Injection Drug Epidemiology (WIDE) Study, Manitoba Health, Manitoba, Canada, 1998.
  42. S. A. Strathdee, D. M. Patrick, C. P. Archibald et al., “Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada,” Addiction, vol. 92, no. 10, pp. 1339–1347, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. Centers for Disease Control and Prevention, Overview of the Cost Effectiveness of HIV Treatment, CDC HIV/AIDS Prevention Programs, Centers for Disease Control and Prevention, Atlanta, GA, USA, 2012.
  44. S. Mostardt, N. Hanhoff, J. Wasem et al., “Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study,” The European Journal of Health Economics. In press.
  45. NASEN, North American Syringe Exchange Network (NASEN), 2011.
  46. EMCDDA, “vention and control of infectious diseases among people who inject drugs,” edited by EMCDDA, European Centre for Disease Prevention and Control, Stockholm, Sweden, 2011.
  47. J. O. Merrill, “Integrating medical care and addiction treatment,” Journal of General Internal Medicine, vol. 18, no. 1, pp. 68–69, 2003. View at Scopus
  48. J. J. Benshoff, L. K. Harrawood, and D. S. Koch, “Substance abuse and the elderly: unique issues and concerns,” Journal of Rehabilitation, vol. 69, no. 2, pp. 43–48, 2003. View at Scopus
  49. J. A. Mitty, V. E. Stone, M. Sands, G. Macalino, and T. Flanigan, “Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress,” Clinical Infectious Diseases, vol. 34, no. 7, pp. 984–990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. G. M. Lucas, P. J. Weidle, S. Hader, and R. D. Moore, “Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study,” Clinical Infectious Diseases, vol. 38, supplement 5, pp. S409–S413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Hagan, “Agent, host, and environment: hepatitis C virus in people who inject drugs,” Journal of Infectious Diseases, vol. 204, no. 12, pp. 1819–1821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Hagan, E. R. Pouget, D. C. Des Jarlais, and C. Lelutiu-Weinberger, “Meta-regression of hepatitis c virus infection in relation to time since onset of illicit drug injection: the influence of time and place,” American Journal of Epidemiology, vol. 168, no. 10, pp. 1099–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Hagan, H. Thiede, and D. C. Des Jarlais, “HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention,” AIDS, vol. 19, supplement 3, pp. S199–S207, 2005. View at Scopus
  54. R. M. Klevens, D. J. Hu, R. Jiles, and S. D. Holmberg, “Evolving epidemiology of hepatitis C virus in the United States,” Clinical Infectious Diseases, vol. 55, supplement 1, pp. S3–S9, 2012.
  55. K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007,” Annals of Internal Medicine, vol. 156, no. 4, pp. 271–278, 2012. View at Scopus
  56. Global Commission on Drug Policy, The War on Drugs and HIV/AIDS: How the Criminalization of Drug Use Fuels the Global Pandemic, edited by Policy GCoD, 2012.
  57. D. C. Des Jarlais, K. Arasteh, C. McKnight, H. Hagan, D. C. Perlman, and S. Semaan, “Associations between herpes simplex virus type 2 and HCV with HIV among injecting drug users in New York City: the current importance of sexual transmission of HIV,” American Journal of Public Health, vol. 101, no. 7, pp. 1277–1283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. A. H. Kral, J. Lorvick, D. Ciccarone et al., “HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco,” Journal of Urban Health, vol. 82, no. 1, supplement, pp. i43–i50, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. A. Strathdee and J. K. Stockman, “Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions,” Current HIV/AIDS Reports, vol. 7, no. 2, pp. 99–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Meader, R. Li, D. C. Des Jarlais, and S. Pilling, “Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users (Review),” Cochrane Database of Systematic Reviews, no. 1, article CD007192, 2010. View at Scopus
  61. J. Cohen, “HIV treatment as prevention,” Science, vol. 334, no. 6063, p. 1628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” The New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. Z. Jia, Y. Ruan, Q. Li et al., “Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–2011): a national observational cohort study,” The Lancet, vol. 6736, no. 12, pp. 61898–61904, 2012.
  64. United States Department of State, Remarks at the 2012 International AIDS Conference: Hillary Rodham Clinton, AIDS, Washington, DC, USA, 2012.
  65. D. Musto, The American Disease: Origins of Narcotic Control, Yale University Press, New Haven, CT, USA, 1973.
  66. D. R. Davis, African Americans and Cocaine: A Historiography, Michigan State University, 2008.
  67. C. G. Vélez-Ibáñez, Border Visions: Mexican Cultures of the Southwest United States, University of ARIZONA Press, Tucson, Ariz, USA, 1996.
  68. D. Hiro, Inside Central Asia: A Political and Cultural History of Uzbekistan, Turkmenistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkey, and Iran, Overlook, New York, NY, USA, 2009.
  69. Division of Criminal Justice Services, 2009 Drug Law Changes, June 2012 Update, Performance OoJRa, Albany, GA, USA.
  70. D. F. Musto, “Opium, cocaine and marijuana in American history,” Scientific American, vol. 265, no. 1, pp. 40–47, 1991. View at Scopus
  71. G. A. Marlatt, M. E. Larimer, and K. A. Witkiewitz, Harm Reduction: Pragmatic Strategies For Managing High-Risk Behaviors, Guilford Publications, New York, NY, USA, 2nd edition, 2011.
  72. R. Pates and D. Riley, Harm Reduction in Substance Use and High-Risk Behaviour, Wiley, Chichester, UK, 2012.
  73. L. Johnston, M. O’Malley, J. Bachman, and J. Schulenberg, Monitoring the Future: National Results on Adolescent Drug Use, The University of Michigan Institute for Social Research, Ann Arbor, Mich, USA, 2011.
  74. United Nations Office on Drugs Crime, Rise in Methamphetamine Abuse Among Youth in SE Asia: Shortage of Qualified Drug Treatment Professionals Hampers Drug Treatment Services, Southeast Asia and Pacific Reports, Crime UNOoDa, Bangkok, Thailand, 2012.
  75. E. Wood, D. Werb, M. Kazatchkine et al., “Vienna declaration: a call for evidence-based drug policies,” The Lancet, vol. 376, no. 9738, pp. 310–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. E. Yamin, “The right to health under international law and its relevance to the United States,” American Journal of Public Health, vol. 95, no. 7, pp. 1156–1161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. World Health Organization, Assessment of Compulsory Treatment of People Who Use Drugs in Cambodia, China, Malaysia and Viet Nam: An Application of Selected Human Rights Principles, WHO, Geneva, Switzerland, 2009.